Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma

@article{Ferrario2017SiltuximabAH,
  title={Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma},
  author={Andrea Ferrario and Michele Merli and Claudia Basilico and Margherita Maffioli and Francesco Passamonti},
  journal={Expert Opinion on Investigational Drugs},
  year={2017},
  volume={26},
  pages={367 - 373}
}
ABSTRACT Introduction: The role of interleukin-6 (IL-6) in tumorigenesis and in particular in haematological malignancies is crucial. On the basis of the favourable results obtained in the subset of multicentric Castleman disease (MCD), Siltuximab, a chimeric, human-murine, immunoglobulin (Ig) Gk monoclonal antibody directed against human IL-6 has been evaluated in haematological malignancies such as multiple myeloma, myelodisplastic syndromes and non Hodgkin lymphomas. Areas covered: This… Expand
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
TLDR
Several novel mAbs directed against NLSAs undergoing clinical evaluation for treating hematological malignancies are reviewed, focusing on the structure of these antibodies, proposed mechanisms of action, efficacy and safety profile in clinical studies, and their potential applications in the treatment of hematology malignancy. Expand
Novel Insights into Membrane Targeting of B Cell Lymphoma.
TLDR
A novel concept is presented in which the plasma membrane organization of the lymphoma B cell determines the efficacy of membrane-targeted therapies, and this has consequences for treatment application and clinical outcome in patients with B cell lymphoma. Expand
Caracterización molecular de la macroglobulinemia de waldenström: implicaciones en el diagnóstico, pronóstico y transformación histológica
TLDR
A whole-exome sequencing study comparing tumor DNA of patients at diagnosis (WM) and transformation to DLBCL showed extensive genetic heterogeneity with a large number of alterations, reflecting the complexity associated with the transformation process. Expand
IL-6 Blockade in Cytokine Storm Syndromes
TLDR
This agent, tocilizumab, has now been used to safely and effectively treat secondary HLH syndromes including those from immune activating cancer therapies such as blinatumomab and chimeric antigen receptor (CAR) T cells. Expand
Tetraspanin CD37 in cell migration and lymphomagenesis. From molecular hypothesis to clinical implications
TLDR
The advances in the microscopy field for the visualization of the plasma membrane as well as the recent progress in targeting microdomains as novel therapeutic approach for infectious and malignant diseases are discussed. Expand
Autoinflammatory Diseases and Cytokine Storms—Imbalances of Innate and Adaptative Immunity
TLDR
A focus on the pathogenesis of autoinflammation and, in particular, of hyperinflammation is provided in order to generate insights for the identification of new therapeutic targets and strategies. Expand
IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets.
TLDR
The interaction between IL-6 and its cellular targets, the IL- 6-dependent tumor resistance mechanisms, and the identification of novel regulators ofIL-6 are some of the highly complex topics included in this review and their understanding could aid cancer biomarkers and therapy development. Expand

References

SHOWING 1-10 OF 68 REFERENCES
Clinical Development of Siltuximab
TLDR
The efficacy of siltuximab in MCD is mainly confined to systemic symptomatic response and quality of life benefits with minimal complete responses and approximately 30 % partial responses, by radiographic criteria. Expand
FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
TLDR
The FDA granted full approval to siltuximab for the treatment of patients with multicentric Castleman disease who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative based on the results of a randomized, double-blind trial. Expand
Cytokine targets in the treatment of myelodysplastic syndromes.
TLDR
Given the biologic heterogeneity of MDS, no single treatment is effective for all patients with the disease, and the future treatment of this challenging disease may lie in combination therapies customized for relevant biologic effectors. Expand
Cytokine deregulation in hematological malignancies: clinical and biological implications.
  • R. Kurzrock
  • Biology, Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1997
TLDR
It is demonstrated that IL-6 levels are elevated in both relapsed and newly diagnosed Hodgkin's and non-Hodgkin's lymphoma and that these levels correlate with established prognostic features, and in diffuse large cell lymphoma, IL- 6 is an independent prognostic variable for both complete remission and failure-free survival. Expand
A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
TLDR
No dose-related or cumulative toxicity was apparent across all disease indications and a dose of 12 mg/kg every 3 weeks was recommended on the basis of the high response rates in Castleman disease and the sustained CRP suppression. Expand
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
TLDR
The pathophysiologic significance of IL-6 in Castleman's disease was confirmed, and blockade of the IL- 6 signal by rhPM-1 is thought to have potential as a new therapy based on the pathophysiological mechanism of multicentric Castleman’s disease. Expand
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
TLDR
Siltuximab plus best supportive care was superior tobest supportive care alone for patients with symptomatic multicentric Castleman's disease and well tolerated with prolonged exposure. Expand
Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma
TLDR
The most common grade 3/4 adverse events, lymphopenia (89 %) and thrombocytopenia (44 %), occurred in patients receiving both doses of siltuximab; however, no dose-limiting toxicities (DLTs) were observed. Expand
Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy.
TLDR
CD responds extremely well to monoclonal antibodies directed at the IL6 receptor or IL6 itself, and in general, the long-term outcome of HIV-negative CD is excellent. Expand
A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: Pathological findings in 15 patients
TLDR
Morphologic similarities indicate a relationship between this multicentric disorder and Castleman's disease of plasmacellular type, however, there are distinct differences between them in clinical presentation and evolution, and, consequently, in therapeutic approach. Expand
...
1
2
3
4
5
...